Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) EPS (Basic) (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of EPS (Basic) data on record, last reported at -$0.49 in Q4 2025.

  • For Q4 2025, EPS (Basic) rose 14.04% year-over-year to -$0.49; the TTM value through Dec 2025 reached -$2.17, up 55.8%, while the annual FY2025 figure was -$2.17, 0.46% changed from the prior year.
  • EPS (Basic) reached -$0.49 in Q4 2025 per CTNM's latest filing, down from -$0.44 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $4.54 in Q2 2023 and bottomed at -$3.55 in Q1 2024.
  • Average EPS (Basic) over 3 years is -$0.48, with a median of -$0.53 recorded in 2024.
  • The widest YoY moves for EPS (Basic): up 85.13% in 2024, down 134.97% in 2024.
  • A 3-year view of EPS (Basic) shows it stood at $1.63 in 2023, then crashed by 134.97% to -$0.57 in 2024, then increased by 14.04% to -$0.49 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.49 in Q4 2025, -$0.44 in Q3 2025, and -$0.62 in Q2 2025.